ZFGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt

zafgen inc (ZFGN) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZAFGEN INC (ZFGN)
\

Related News

No related news articles were found.

zafgen inc (ZFGN) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZFGN) Details

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and liver diseases. Its lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase II clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. The company also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS; and ZGN-1345, an orally dosed MetAP2 inhibitor specifically targeting the liver. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

38 Employees
Last Reported Date: 03/14/19
Founded in 2005

zafgen inc (ZFGN) Top Compensated Officers

CEO & Director
Total Annual Compensation: $748.6K
Chief Financial Officer
Total Annual Compensation: $443.6K
Chief Business Officer
Total Annual Compensation: $300.6K
Compensation as of Fiscal Year 2018.
zafgen inc
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

Zafgen, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating loss was USD 13.277 million compared to USD 15.702 million a year ago. Net loss was USD 13.112 million compared to USD 15.956 million a year ago. Basic loss per share was USD 0.35 compared to USD 0.58 a year ago.

Zafgen, Inc. to Report Q1, 2019 Results on May 09, 2019

Zafgen, Inc. announced that they will report Q1, 2019 results at 5:00 PM, Eastern Standard Time on May 09, 2019

Zafgen, Inc. Presents at 31st Annual ROTH Conference, Mar-19-2019 11:30 AM

Zafgen, Inc. Presents at 31st Annual ROTH Conference, Mar-19-2019 11:30 AM. Venue: The Ritz Carlton, Laguna Niguel, Dana Point, California, United States. Speakers: Jeffrey S. Hatfield, CEO & Director.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ZFGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZFGN.
View Industry Companies
 

Industry Analysis

ZFGN

Industry Average

Valuation ZFGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.